Valuation: Harvard Bioscience, Inc.

Market Cap 37.97M 33.73M 31.48M 28.7M 54.12M 3.65B 54.63M 381M 148M 1.87B 143M 139M 5.99B P/E 2026 *
-4.29x
P/E 2027 * -17.9x
Enterprise Value 37.97M 33.73M 31.48M 28.7M 54.12M 3.65B 54.63M 381M 148M 1.87B 143M 139M 5.99B EV / Sales 2026 *
0.42x
EV / Sales 2027 * 0.4x
Free-Float
90.61%
Yield 2026 *
-
Yield 2027 * -
1 day+2.58%
1 week+4.77%
Current month+5.30%
1 month+4.25%
3 months+35.61%
6 months+60.38%
Current year+24.70%
1 week 7.85
Extreme 7.85
8.42
1 month 7.85
Extreme 7.85
8.42
Current year 4
Extreme 4
8.42
1 year 3.76
Extreme 3.755
9.4
3 years 2.81
Extreme 2.813
55.6
5 years 2.81
Extreme 2.813
82.3
10 years 2.81
Extreme 2.813
87.5
Manager TitleAgeSince
Chief Executive Officer 55 28/07/2025
Director of Finance/CFO 63 12/05/2025
Chief Tech/Sci/R&D Officer - 01/04/2019
Director TitleAgeSince
Director/Board Member 52 24/10/2017
Director/Board Member 55 02/06/2025
Director/Board Member 52 16/07/2025
Date Insider Type Main position Quantity % Market Cap. Importance
20/3/26 Free

Chief Executive Officer

75,000 0.1677%
20/3/26 Free

Chief Financial Officer

30,000 0.0671%
17/3/26 Buy

Director

10,000 0.0224%
Change 5-day change 1-year change 3-year change Capi.($)
+2.58%+4.77%+85.75%-80.51% 37.97M
+0.35%-2.99%+20.52%+31.06% 242B
+1.09%-4.65%-0.43%-0.76% 150B
-2.32%-3.27%-13.35%+36.07% 138B
-1.46%-3.01%-56.23%-17.35% 61.74B
-0.05%-1.32%+10.48%+22.34% 49.08B
+0.66%+0.19%-20.53%-20.70% 47.43B
+0.66%-2.90%+18.46%+52.17% 47.3B
-3.05%-2.62%-7.75%+36.49% 44.25B
-0.08%-1.92%+29.48%+60.45% 41.78B
Average -0.16%-1.78%+6.64%+11.93% 82.27B
Weighted average by Cap. -0.29%-3.27%+1.08%+21.94%

Financials

2026 *2027 *
Net sales 89.8M 79.79M 74.47M 67.88M 128M 8.63B 129M 901M 349M 4.41B 337M 330M 14.16B 94.55M 84.01M 78.41M 71.47M 135M 9.09B 136M 949M 368M 4.65B 355M 347M 14.91B
Net income -8.9M -7.91M -7.38M -6.73M -12.69M -856M -12.81M -89.32M -34.61M -437M -33.42M -32.69M -1.4B -2.2M -1.95M -1.82M -1.66M -3.14M -211M -3.17M -22.08M -8.56M -108M -8.26M -8.08M -347M
Net Debt - -
Logo Harvard Bioscience, Inc.
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Employees
328
Date Price Change Volume
02/10/26 USD 8.340 +2.58% 15,471
01/10/26 USD 8.130 +2.65% 45,716
30/09/26 USD 7.920 -0.50% 15,104
29/09/26 USD 7.960 -0.25% 26,612
28/09/26 USD 7.980 +0.25% 32,313
Trader
-
Investor
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
8.340USD
Average target price
7.500USD
Spread / Average Target
-10.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HBIO Stock